A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trials.
Sebio A, Stintzing S, Heinemann V, Sunakawa Y, Zhang W, Ichikawa W, Tsuji A, Takahashi T, Parek A, Yang D, Cao S, Ning Y, Stremitzer S, Matsusaka S, Okazaki S, Barzi A, Berger MD, Lenz HJ.
Sebio A, et al. Among authors: lenz hj.
Pharmacogenomics J. 2018 Jan;18(1):43-48. doi: 10.1038/tpj.2016.69. Epub 2016 Oct 4.
Pharmacogenomics J. 2018.
PMID: 27698403
Free PMC article.